Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans

A Benso, DH St-Pierre, F Prodam, E Gramaglia, R Granata, AJ (Aart-Jan) van der Lely, E Ghigo, F (Fabio) Broglio

Research output: Contribution to journalArticleAcademicpeer-review

63 Citations (Scopus)
3 Downloads (Pure)

Abstract

Objective: To clarify the metabolic effects of an overnight i.v. infusion of unacylated ghrelin (UAG) in humans. UAG exerts relevant metabolic actions, likely mediated by a still unknown ghrelin receptor subtype, including effects on beta-cell viability and function, insulin secretion and sensitivity, and glucose and lipid metabolism. Design: We studied the effects of a 16-h infusion (from 2100 to 1300 h) of UAG (1.0 mu g/kg per h) or saline in eight normal subjects (age (mean +/- S.E.M.), 29.6 +/- 2.4 years; body mass index (BMI), 22.4 +/- 1.7 kg/m(2)), who were served, at 2100 and 0800 h respectively, with isocaloric balanced dinner and breakfast. Glucose, insulin, and free fatty acid (FFA) levels were measured every 20 min. Results: In comparison with saline, UAG induced significant (P < 0.05) changes in glucose, insulin, and FFA profiles. UAG infusion decreased glucose area under the curve (AUC) values by 10% (UAG(0-960) (min) :79.0 +/- 1.7 X 10(3) mg/dl per min vs saline(0-960) (min): 87.5 +/- 3.8 X 10(3) mg/dl per min) and the AUC at night by 14% (UAG(180-660) (min): 28.4 +/- 0.5 X 10(3) mg/dl per min vs saline(180-660) (min): 33.2 +/- 1.1 X 10(3) mg/dl per min). The overall insulin AUC was not significantly mod Conclusions: Exposure to the i.v. administration of UAG improves glucose metabolism and inhibits lipolysis in healthy volunteers. Thus, in contrast to the diabetogenic action of AG, UAG displays hypoglycemic properties.
Original languageUndefined/Unknown
Pages (from-to)911-916
Number of pages6
JournalEuropean Journal of Endocrinology
Volume166
Issue number5
DOIs
Publication statusPublished - 2012

Cite this